Key takeaways
- 500,000+ US patients aged 70+ with HFpEF estimated to have undiagnosed ATTRwt-CM, vs only 70,000-100,000 currently diagnosed and treated
- 10,000–15,000/yr Annual new US ATTR-CM diagnoses — the volume a new entrant should target, not tafamidis switches
- $13K–17K vs $225K ICER's tafamidis fair-value range vs actual WAC — the steepest value gap in the rare-disease basket, and the benchmark a new stabilizer will be measured against
- 100,000+ Estimated African American Val122Ile ATTRv carriers, most undiagnosed — an underused genetic-testing and case-finding opportunity
The binding constraint: capture newly diagnosed ATTR-CM volume, not switch stable tafamidis patients, while surviving ICER's steepest value gap in the rare-disease basket.
Tafamidis (Vyndaqel) holds roughly 60% of the ATTR-CM stabilizer market, but the more important fact for a pre-launch entrant is that this market is expanding rapidly, not fixed: an estimated 500,000+ US patients aged 70+ with HFpEF have undiagnosed ATTRwt-CM, against only 70,000-100,000 currently diagnosed and treated, and annual new diagnoses are running at 10,000-15,000 as Tc-PYP scintigraphy awareness grows. Acoramidis (Attruby, approved November 2024) has built 15-20% share almost entirely from newly diagnosed patients rather than tafamidis switches — confirming that capturing new diagnosis volume, not displacing the incumbent, is the correct commercial model for a new entrant.
Two structural sub-populations remain underdiagnosed and largely untapped: ATTRv (hereditary) carriers, including an estimated 100,000+ African American Val122Ile carriers (most undiagnosed, 3-4% carrier rate); and ATTR-PN (polyneuropathy), where a 4-5 year misdiagnosis delay (commonly mistaken for CIDP or diabetic neuropathy) hides 5,000-10,000 hereditary patients against only 3,000-4,000 currently diagnosed and treated. The competitive landscape is also mechanistically bifurcating (stabilizers such as tafamidis and acoramidis versus knockdown therapy such as vutrisiran, ATTR-PN approved, BLA pending for ATTR-CM), raising an unresolved commercial question a new entrant must answer: is your drug positioned as a stand-alone stabilizer, a combination partner, or a replacement mechanism?
The single most severe payer risk in this basket is ICER's tafamidis assessment: a published fair-value range of $13,000-17,000/year against a $225,000/year WAC — a 12-17x gap that has driven commercial payers to negotiate estimated net prices 40-60% below WAC. A new ATTR-CM stabilizer should expect the same scrutiny and plan pricing (likely $200,000-250,000/year WAC with comparable rebate exposure) accordingly. Pre-launch priorities: map US cardiologists ordering Tc-PYP by territory now, partner with commercial genetics labs to expand Val122Ile and TTR-gene screening in African American communities, engage community neurologists on ATTR-PN diagnostic criteria to recover the misdiagnosed backlog, and begin ICER engagement and Part D PBM contracting 18-24 months ahead of launch.
Current ATTR standard of care — US, 2024
| Drug (Brand / INN) | Mechanism | US Share | WAC | Segment Addressed | Payer Posture |
|---|---|---|---|---|---|
| Vyndaqel (tafamidis) | Oral TTR stabilizer | ~60% ATTR-CM share | ~$225,000/yr WAC | ATTR-CM, broad label | ICER fair value $13-17K vs WAC; net price ~40-60% below WAC post-rebate |
| Attruby (acoramidis) | Oral TTR stabilizer | ~15-20% share (newly diagnosed growth) | ~$225,000-250,000/yr WAC | Newly diagnosed ATTR-CM | Same PA framework as tafamidis; ICER scrutiny expected |
| Amvuttra (vutrisiran) | siRNA SC q12w | ATTR-PN approved SoC; CM BLA pending | Part D specialty (ATTR-PN); CM WAC not yet set | ATTR-PN today; potential ATTR-CM pending FDA review | Part D specialty; mechanism bifurcation from oral stabilizers |
Sources: IQVIA ATTR-CM diagnosis trends 2024; Pfizer tafamidis commercial data; BridgeBio investor day 2024; Alnylam ATTR prescriber analysis 2024; Ruberg FL et al. Circulation 2019; Quarta CC et al. NEJM 2015 (Val122Ile); Adams D et al. Lancet Neurol 2021 (ATTRv-PN); ICER tafamidis ATTR-CM value assessment 2021; UHC ATTR-CM PA criteria 2024.
What this assessment answers
Every section answers a named commercial question your team is asking, scoped to your asset.
- Should a new ATTR-CM stabilizer target newly diagnosed patients or attempt to switch stable tafamidis/acoramidis patients, and what does acoramidis's launch prove about which model works? • Newly diagnosed vs switch-share analysis from acoramidis's 2024 launch • cardiologist prescribing-decision framework for newly diagnosed ATTR-CM • combination-therapy positioning question (stabilizer + vutrisiran)
- How large is the underdiagnosed ATTRv/Val122Ile and ATTR-PN opportunity, and what case-finding infrastructure should be built pre-launch? • Val122Ile African American carrier sizing (100,000+) • ATTR-PN misdiagnosis-delay backlog (5,000-10,000 patients, 4-5yr delay) • genetics-lab partnership and community-neurology engagement design
- What ICER-style value scrutiny should a new ATTR-CM stabilizer plan for, and what PBM/Part D access architecture is required at launch? • ICER tafamidis fair-value benchmark ($13-17K vs $225K WAC) and net-price rebate exposure • PA criteria (Tc-PYP Grade 2-3, NYHA I-II, eGFR>25) • Part D PBM contracting timeline (UHC/Optum, CVS/Caremark, Express Scripts)
What's inside
-
1 · The Binding Constraint 2 pp
- Capturing newly diagnosed ATTR-CM volume vs switching stable stabilizer patients
- Pressure-tested against ICER's steep tafamidis value gap
-
2 · Standard-of-Care Landscape & Entrenchment 5 pp
- Tafamidis incumbency and acoramidis's newly-diagnosed growth model
- Vutrisiran's siRNA mechanism bifurcation (ATTR-PN approved, CM BLA pending)
- Combination therapy positioning question for cardiologists and payers
-
3 · Target Population & Unmet Need 5 pp
- ATTRwt-CM diagnosis-to-treatment gap (500,000+ undiagnosed vs 70-100K treated)
- Val122Ile African American ATTRv carrier opportunity (100,000+)
- ATTR-PN misdiagnosis backlog (4-5 year delay, 5,000-10,000 hereditary patients)
-
4 · Anticipated Payer & Access Posture 5 pp
- PA criteria (Tc-PYP Grade 2-3/biopsy, NYHA I-II, eGFR>25, cardiology specialist)
- ICER tafamidis fair-value benchmark and net-price rebate exposure
- Part B vs Part D pathway and PBM contracting timeline
-
5 · The Assumption Register 2 pp
- Every population, share, and pricing figure sourced and confidence-rated
- Built to survive an internal challenge meeting
-
6 · KOL & Centre Readiness 3 pp
- ~150 academic ATTR cardiologist KOLs vs ~50 specialist ATTR-PN neurologists
- Cardiologist vs neurologist segmentation strategy
- Pre-launch engagement sequencing
-
7 · Client Alignment Questions 2 pp
- Open decisions on combination-therapy positioning and pricing tier
- Structured for an advisory board or internal alignment session
Appendix and source ledger included · 45-minute analyst readout included with delivery
Custom assessment delivered in 72 hours.
Assess this reportIncluded with every brief
Get Started
Commission this assessment
AXLRx delivers ATTR amyloidosis launch-readiness intelligence built for pre-launch commercial, medical affairs, and market access teams. Custom assessment in 72 hours.
- 1. Submit your requestUse the intake form to specify your asset, target population, and pre-launch question.
- 2. Scoping callAXLRx analyst confirms scope, comparators, and access-architecture assumptions.
- 3. DeliveryResearch-verified assessment in 72 hours with optional analyst readout.
How AXLRx builds this assessment
Prepared by MoatRx analysts on the AXLRx commercial consulting engine.
This assessment synthesises three independent research angles (competitive positioning, target-population epidemiology, and anticipated payer posture) into one integrated pre-launch view. Every figure is drawn from the named primary source in the underlying research base and cross-checked before inclusion; no figure is carried from model memory.
ATTR launch-readiness sources: IQVIA ATTR-CM diagnosis trends 2024; Pfizer tafamidis commercial data; BridgeBio investor day 2024; Alnylam ATTR prescriber analysis 2024 and HELIOS-B analysis; Ruberg FL et al., Circulation 2019; Quarta CC et al., NEJM 2015 (Val122Ile); Invitae TTR gene panel; Adams D et al., Lancet Neurol 2021 (ATTRv-PN); ICER tafamidis ATTR-CM value assessment 2021; UHC/Cigna ATTR-CM PA criteria 2024; AHA ATTR heart failure committee 2024.
- Drug approval dates and mechanism claims verified against FDA approval records referenced in the source research base
- Clinical trial results (ATTR-ACT, ATTRibute-CM, HELIOS-B) verified against the named primary publications in the source research base
- Payer PA-criteria and ICER value-assessment figures cross-checked against named payer and ICER sources in the source research base
- Anticipated payer posture is explicitly flagged as anticipated, not confirmed policy, and separated from verified clinical/regulatory facts
Frequently asked questions
Deliverables What formats are included with every assessment?
Every commissioned Launch Readiness assessment includes a 24-30 page PDF covering the binding constraint, SoC entrenchment, target-population sizing, and anticipated payer posture; an editable Excel population-sizing and access-scenario model; and a 12-15 slide PowerPoint readout. A 45-minute analyst call is included with delivery.
Sources How are figures verified for a pre-launch assessment?
Every figure is cited to a live source at the point of writing and cross-checked in an independent audit pass: diagnosis-trend data, manufacturer and investor disclosures, prescriber analyses, and the published cardiac-amyloidosis prevalence literature. Anticipated payer posture is explicitly distinguished from confirmed policy throughout.
Customisation Can I tailor scope to my specific asset or target population?
Yes. The intake form captures your asset's mechanism, target patient segment, and the specific pre-launch question you need answered — a scoping call confirms comparators and access-architecture assumptions before research begins.